Comparative Pharmacology
Head-to-head clinical analysis: HYDROCORTISONE ACETATE versus TRIACIN C.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCORTISONE ACETATE versus TRIACIN C.
HYDROCORTISONE ACETATE vs TRIACIN-C
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocortisone acetate is a synthetic glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression. It exerts anti-inflammatory, immunosuppressive, and vasoconstrictive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
TRIACIN-C is a combination of triamcinolone (a corticosteroid) and nystatin (an antifungal). Triamcinolone suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis. Nystatin binds to ergosterol in fungal cell membranes, causing pore formation and cell death.
Hydrocortisone acetate is typically administered as a topical, intra-articular, intradermal, or rectal preparation. For intra-articular use, adult dose: 5-50 mg (depending on joint size) every 1-2 weeks. For rectal use, 25 mg (one suppository) twice daily or 1 application of foam or enema (10% or 1% respectively) once or twice daily. For intradermal injection, 1-2 mL (25 mg/mL) into lesion every 1-2 weeks. Note: Systemic dosing is not applicable as it is not used for systemic effects due to low bioavailability.
5 mg orally twice daily, taken with meals to enhance absorption.
None Documented
None Documented
Terminal elimination half-life: 1-2 hours for endogenous hydrocortisone; with acetate ester, extended to ~2-4 hours due to slower absorption and hydrolysis. Clinical context: Duration of action exceeds half-life due to intracellular receptor binding.
Terminal elimination half-life: 7–9 hours. In patients with severe hepatic impairment (Child-Pugh C), half-life may extend to 15 hours; dosing adjustment recommended.
Renal: ~80% as metabolites (glucuronide and sulfate conjugates) and <1% unchanged; fecal: <5% via biliary elimination.
Renal: ~60% as unchanged drug; hepatic metabolism accounts for ~25% (primarily via CYP3A4), with biliary excretion of metabolites (~15%); fecal elimination <5%.
Category D/X
Category C
Corticosteroid
Corticosteroid